Jonathan I. Lieber

CIK: 0001350090

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (20.0%)

Position reduction

Option Exercises (M)4 (40.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RLYB

Rallybio Corp

Officer

BBTX

Bambusa Therapeutics, Inc.

Officer

DCOY

Decoy Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

RLYB
Rallybio Corp
Oct 29, 2026
Exercise(M)
Direct
13.6K shares at avg. $6.08$83K
RLYB
Rallybio Corp
Oct 29, 2026
Exercise(M)
Direct
7.9K shares at avg. $14.88$117K
RLYB
Rallybio Corp
Oct 27, 2026
Sale(S)
Direct
599 shares at avg. $16.04$10K
RLYB
Rallybio Corp
Oct 26, 2026
Award(A)
Direct
2.5K shares-
RLYB
Rallybio Corp
Oct 9, 2026
Exercise(M)
Direct
3.9K shares at avg. $6.08$24K
RLYB
Rallybio Corp
Sep 29, 2026
Exercise(M)
Direct
5K shares at avg. $6.08$30K
DCOY
Decoy Therapeutics Inc.
Aug 31, 2026
Award(A)
Direct
2K shares-
RLYB
Rallybio Corp
Feb 23, 2026
Sale(S)
Direct
789 shares at avg. $5.06$4K
RLYB
Rallybio Corp
Feb 18, 2026
Award(A)
Direct
2.5K shares-
RLYB
Rallybio Corp
Feb 14, 2025
Award(A)
Option (Right to Buy)
Direct
180K shares-

		Type	Shares	Price		Ownership
Oct 29, 2026	RLYB Rallybio Corp	Exercise(M)	13,589	$6.08	$82,621	Direct
Oct 29, 2026	RLYB Rallybio Corp	Exercise(M)	7,875	$14.88	$117,180	Direct
Oct 27, 2026	RLYB Rallybio Corp	Sale(S)	599	$16.04	$9,608	Direct
Oct 26, 2026	RLYB Rallybio Corp	Award(A)	2,500	-	$0	Direct
Oct 9, 2026	RLYB Rallybio Corp	Exercise(M)	3,910	$6.08	$23,773	Direct
Sep 29, 2026	RLYB Rallybio Corp	Exercise(M)	5,000	$6.08	$30,400	Direct
Aug 31, 2026	DCOY Decoy Therapeutics Inc.	Award(A)	2,000	-	$0	Direct
Feb 23, 2026	RLYB Rallybio Corp	Sale(S)	789	$5.06	$3,992	Direct
Feb 18, 2026	RLYB Rallybio Corp	Award(A)	2,500	-	$0	Direct
Feb 14, 2025	RLYB Rallybio Corp	Award(A) Option (Right to Buy)	180,000	-	-	Direct

1-10 of 10 transactions

About Lieber Jonathan I

Lieber Jonathan I (SEC CIK 0001350090) files insider reports with the SEC as Chief Financial Officer of Rallybio Corp (RLYB), Chief Financial Officer of Bambusa Therapeutics, Inc. (BBTX) and Director of Decoy Therapeutics Inc. (DCOY).

Signal8 holds 8 ownership filings by Lieber Jonathan I (1 Form 3, 7 Form 4), filed between Feb 19, 2025 and Nov 2, 2026. Those filings report 10 transactions, from Feb 14, 2025 to Oct 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lieber Jonathan I's filings is in EAST BERLIN, CT.

Recent filings by Lieber Jonathan I

Oct 29, 2026: Option exercises of RLYB shares (2 lines, Form 4, code M).
Oct 27, 2026: Open-market sale of RLYB shares (Form 4, code S).
Oct 26, 2026: Grant or award of RLYB shares (Form 4, code A).
Oct 9, 2026: Option exercise of RLYB shares (Form 4, code M).
Sep 29, 2026: Option exercise of RLYB shares (Form 4, code M).

Other insiders filing for Rallybio Corp (RLYB)

HUNT RONALD, Director
Nash Christine A, Director
Uden Stephen, Chief Executive Officer
Chung Wendy, Director
Soteropoulos Paula, Director
Boudreau Helen M, Director

How to read Form 4 transaction codes